A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
Abstract Mutations and transient conformational movements of receptor binding domain (RBD) that make neutralizing epitopes momentarily unavailable, present immune escape routes to SARS-CoV-2. To mitigate viral escape, we developed a cocktail of neutralizing antibodies (NAbs) targeting epitopes located on different domains of spike (S) protein. Screening of a library of monoclonal antibodies generated from peripheral blood mononuclear cells of COVID-19 convalescent patients yielded potent NAbs, targeting N-terminal domain (NTD) and RBD domain of S, effective atnMconcentrations. Remarkably, combination of RBD-targeting NAbs and NTD-binding NAb, FC05, dramatically enhanced the neutralization potency in cell-based assays and animal model. Results of competitive SPR assays and cryo-EM structures of Fabs bound to S unveil determinants of immunogenicity. Combinations of immunogens, identified in NTD and RBD of S, when immunized in rabbits elicited potent protective immune responses against SARS-CoV-2. These results provide a proof-of-concept for neutralization-based immunogen design targeting SARS-CoV-2 NTD and RBD.One sentence summary Immunogens identified in the NTD and RBD of the SARS-CoV-2 spike protein using a cocktail of non-competing NAbs when injected in rabbits elicited a potent protective immune response against SARS-CoV-2..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 15. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Li [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.09.23.309294 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018808069 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018808069 | ||
| 003 | DE-627 | ||
| 005 | 20230429100317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200924s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.09.23.309294 |2 doi | |
| 035 | |a (DE-627)XBI018808069 | ||
| 035 | |a (biorXiv)10.1101/2020.09.23.309294 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Mutations and transient conformational movements of receptor binding domain (RBD) that make neutralizing epitopes momentarily unavailable, present immune escape routes to SARS-CoV-2. To mitigate viral escape, we developed a cocktail of neutralizing antibodies (NAbs) targeting epitopes located on different domains of spike (S) protein. Screening of a library of monoclonal antibodies generated from peripheral blood mononuclear cells of COVID-19 convalescent patients yielded potent NAbs, targeting N-terminal domain (NTD) and RBD domain of S, effective atnMconcentrations. Remarkably, combination of RBD-targeting NAbs and NTD-binding NAb, FC05, dramatically enhanced the neutralization potency in cell-based assays and animal model. Results of competitive SPR assays and cryo-EM structures of Fabs bound to S unveil determinants of immunogenicity. Combinations of immunogens, identified in NTD and RBD of S, when immunized in rabbits elicited potent protective immune responses against SARS-CoV-2. These results provide a proof-of-concept for neutralization-based immunogen design targeting SARS-CoV-2 NTD and RBD.One sentence summary Immunogens identified in the NTD and RBD of the SARS-CoV-2 spike protein using a cocktail of non-competing NAbs when injected in rabbits elicited a potent protective immune response against SARS-CoV-2. | ||
| 700 | 1 | |a Cao, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xing-Su |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Bin-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Yong-Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Bian, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Xi-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Hong-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Geng |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Kui-Kui |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yu-Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Hong-Xing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Bao-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Cheng-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiangxi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Feng-Cai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 15. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:15 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1093/nsr/nwab053 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.09.23.309294 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 15 |c 12 | ||
| 953 | |2 045F |a 570 | ||